Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease

Nobuo Itoh; Hiroyuki Arai; Katsuya Urakami; Koichi Ishiguro; Hideto Ohno; Harald Hampel; Katharina Buerger; Jens Wiltfang; Markus Otto; Hans Kretzschmar; Hans Juergen Moeller; Masaki Imagawa; Hideki Kohno; Kenji Nakashima; Shigeki Kuzuhara; Hidetada Sasaki; Kazutomo Imahori

doi:10.1002/ana.1054

Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease

Nobuo Itoh, Hiroyuki Arai, Katsuya Urakami, Koichi Ishiguro, Hideto Ohno, Harald Hampel, Katharina Buerger, Jens Wiltfang, Markus Otto, Hans Kretzschmar, Hans Juergen Moeller, Masaki Imagawa, Hideki Kohno, Kenji Nakashima, Shigeki Kuzuhara, Hidetada Sasaki, Kazutomo Imahori

Research output: Contribution to journal › Article › peer-review

198 Citations (Scopus)

Abstract

We surveyed a total of 570 cerebrospinal fluid (CSF) samples from a variety of diseases, including Alzheimer's disease (AD; n = 236), non-AD-demented and nondemented diseases (n = 239), and normal controls (n = 95) to quantitate levels of tau protein phosphorylated at serine 199 (CSF/phospho-tau₁₉₉) by a recently established sandwich ELISA. The CSF/phospho-tau₁₉₉levels in the AD group were significantly elevated compared to those in all the other non-AD groups. Receiver operating characteristics curves showed that the diagnostic sensitivity and specificity for the AD group vs all the other non-AD groups using the CSF/phospho-tau₁₉₉were 85.2% and 85.0%, respectively. Furthermore, there was a significant positive correlation between CSF/phospho-tau₁₉₉and CSF/total-tau levels in the AD group. Elevated CSF/phospho-tau₁₉₉in the AD group was noted irrespective of age, gender, dementia severity, and number of apolipoprotein E4 alleles. Thus, we suggest that CSF/phospho-tau₁₉₉may be a novel and logical biomarker in supporting antemortem diagnosis of AD.

Original language	English
Pages (from-to)	150-156
Number of pages	7
Journal	Annals of Neurology
Volume	50
Issue number	2
DOIs	https://doi.org/10.1002/ana.1054
Publication status	Published - 2001
Externally published	Yes

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.1002/ana.1054

Cite this

Itoh, N., Arai, H., Urakami, K., Ishiguro, K., Ohno, H., Hampel, H., Buerger, K., Wiltfang, J., Otto, M., Kretzschmar, H., Moeller, H. J., Imagawa, M., Kohno, H., Nakashima, K., Kuzuhara, S., Sasaki, H., & Imahori, K. (2001). Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. Annals of Neurology, 50(2), 150-156. https://doi.org/10.1002/ana.1054

Itoh, N, Arai, H, Urakami, K, Ishiguro, K, Ohno, H, Hampel, H, Buerger, K, Wiltfang, J, Otto, M, Kretzschmar, H, Moeller, HJ, Imagawa, M, Kohno, H, Nakashima, K, Kuzuhara, S, Sasaki, H & Imahori, K 2001, 'Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease', Annals of Neurology, vol. 50, no. 2, pp. 150-156. https://doi.org/10.1002/ana.1054

@article{a130c58dbda74a25aca26995a8463983,

title = "Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease",

abstract = "We surveyed a total of 570 cerebrospinal fluid (CSF) samples from a variety of diseases, including Alzheimer's disease (AD; n = 236), non-AD-demented and nondemented diseases (n = 239), and normal controls (n = 95) to quantitate levels of tau protein phosphorylated at serine 199 (CSF/phospho-tau199) by a recently established sandwich ELISA. The CSF/phospho-tau199levels in the AD group were significantly elevated compared to those in all the other non-AD groups. Receiver operating characteristics curves showed that the diagnostic sensitivity and specificity for the AD group vs all the other non-AD groups using the CSF/phospho-tau199were 85.2% and 85.0%, respectively. Furthermore, there was a significant positive correlation between CSF/phospho-tau199and CSF/total-tau levels in the AD group. Elevated CSF/phospho-tau199in the AD group was noted irrespective of age, gender, dementia severity, and number of apolipoprotein E4 alleles. Thus, we suggest that CSF/phospho-tau199may be a novel and logical biomarker in supporting antemortem diagnosis of AD.",

author = "Nobuo Itoh and Hiroyuki Arai and Katsuya Urakami and Koichi Ishiguro and Hideto Ohno and Harald Hampel and Katharina Buerger and Jens Wiltfang and Markus Otto and Hans Kretzschmar and Moeller, {Hans Juergen} and Masaki Imagawa and Hideki Kohno and Kenji Nakashima and Shigeki Kuzuhara and Hidetada Sasaki and Kazutomo Imahori",

year = "2001",

doi = "10.1002/ana.1054",

language = "English",

volume = "50",

pages = "150--156",

journal = "Annals of Neurology",

issn = "0364-5134",

publisher = "John Wiley and Sons Inc.",

number = "2",

}

TY - JOUR

T1 - Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease

AU - Itoh, Nobuo

AU - Arai, Hiroyuki

AU - Urakami, Katsuya

AU - Ishiguro, Koichi

AU - Ohno, Hideto

AU - Hampel, Harald

AU - Buerger, Katharina

AU - Wiltfang, Jens

AU - Otto, Markus

AU - Kretzschmar, Hans

AU - Moeller, Hans Juergen

AU - Imagawa, Masaki

AU - Kohno, Hideki

AU - Nakashima, Kenji

AU - Kuzuhara, Shigeki

AU - Sasaki, Hidetada

AU - Imahori, Kazutomo

PY - 2001

Y1 - 2001

N2 - We surveyed a total of 570 cerebrospinal fluid (CSF) samples from a variety of diseases, including Alzheimer's disease (AD; n = 236), non-AD-demented and nondemented diseases (n = 239), and normal controls (n = 95) to quantitate levels of tau protein phosphorylated at serine 199 (CSF/phospho-tau199) by a recently established sandwich ELISA. The CSF/phospho-tau199levels in the AD group were significantly elevated compared to those in all the other non-AD groups. Receiver operating characteristics curves showed that the diagnostic sensitivity and specificity for the AD group vs all the other non-AD groups using the CSF/phospho-tau199were 85.2% and 85.0%, respectively. Furthermore, there was a significant positive correlation between CSF/phospho-tau199and CSF/total-tau levels in the AD group. Elevated CSF/phospho-tau199in the AD group was noted irrespective of age, gender, dementia severity, and number of apolipoprotein E4 alleles. Thus, we suggest that CSF/phospho-tau199may be a novel and logical biomarker in supporting antemortem diagnosis of AD.

AB - We surveyed a total of 570 cerebrospinal fluid (CSF) samples from a variety of diseases, including Alzheimer's disease (AD; n = 236), non-AD-demented and nondemented diseases (n = 239), and normal controls (n = 95) to quantitate levels of tau protein phosphorylated at serine 199 (CSF/phospho-tau199) by a recently established sandwich ELISA. The CSF/phospho-tau199levels in the AD group were significantly elevated compared to those in all the other non-AD groups. Receiver operating characteristics curves showed that the diagnostic sensitivity and specificity for the AD group vs all the other non-AD groups using the CSF/phospho-tau199were 85.2% and 85.0%, respectively. Furthermore, there was a significant positive correlation between CSF/phospho-tau199and CSF/total-tau levels in the AD group. Elevated CSF/phospho-tau199in the AD group was noted irrespective of age, gender, dementia severity, and number of apolipoprotein E4 alleles. Thus, we suggest that CSF/phospho-tau199may be a novel and logical biomarker in supporting antemortem diagnosis of AD.

UR - http://www.scopus.com/inward/record.url?scp=0034899223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034899223&partnerID=8YFLogxK

U2 - 10.1002/ana.1054

DO - 10.1002/ana.1054

M3 - Article

C2 - 11506396

AN - SCOPUS:0034899223

SN - 0364-5134

VL - 50

SP - 150

EP - 156

JO - Annals of Neurology

JF - Annals of Neurology

IS - 2

ER -

Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this